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Abstract
This study seeks to measure the treatment effect of glucose–insulin–potassium (GIK) infusion on
mortality in critically ill patients. A systematic review of randomized controlled trials is
conducted, comparing GIK treatment with standard care or placebo in critically ill adult patients.
The primary outcome variable is mortality. Two authors independently extract data and assess
study quality. The primary analysis is based on the random effects model to produce pooled odds
ratios (ORs) with 95% confidence intervals (CIs). The search yields 1720 potential publications;
23 studies are included in the final analysis, providing a sample of 22 525 patients. The combined
results demonstrate no heterogeneity (P = .57, I2 = 0%) and no effect on mortality (OR = 1.02;
95% CI, 0.93–1.11) with GIK treatment. No experimental studies of shock or sepsis populations
are identified. This meta-analysis finds that there is no mortality benefit to GIK infusion in
critically ill patients; however, study populations are limited to acute myocardial infarction and
cardiovascular surgery patients. No studies are identified using GIK in patients with septic shock
or other forms of circulatory shock, providing an absence of evidence regarding the effect of GIK
as a therapy in patients with shock.
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Infusion of a glucose–insulin–potassium (GIK) solution was first proposed in the 1960s as
treatment for acute myocardial infarction (AMI) with the intention of providing electrical
stability to the myocardium.1 The proposed mechanisms of action of GIK therapy in
cardiovascular disease include suppression of circulating levels and myocardial uptake of
free fatty acids, which are toxic to ischemic myocardium; improvement in the efficiency of
myocardial energy production through the provision of exogenous glucose; and stabilization
of intracellular potassium, which may be depleted during times of myocardial ischemia.2,3
Since the sentinel report, numerous randomized controlled trials have been performed using
GIK. Pooled data have suggested morbidity and mortality benefits associated with GIK
therapy in cardiothoracic surgery4 and AMI3 populations. The largest GIK study performed
in AMI patients to date failed to find similar benefits.2 Thus, there remain significant
conflicting evidence and debate regarding the utility of GIK infusion in various patient
populations.
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Extensive preclinical rationales support the use of GIK as an inotropic and metabolic
therapy in several critical illnesses. The heart develops insulin resistance in shock and
sepsis, and insulin-euglycemia produces a potent inotropic effect on the left ventricle.5,6
Sepsis can lead to excessive phosphorylation of the pyruvate dehydrogenase complex, thus
impairing net carbohydrate oxidation in skeletal and heart muscle.7–9 Deficits in
carbohydrate oxidation can be expected to be worsened by the effect of diabetes mellitus, a
common comorbidity in humans.10 Insulin reactivates the pyruvate dehydrogenase complex,
via activation of pyruvate dehydrogenase phosphatase, to permit maximal glucose and
lactate oxidation by heart muscle.11 Additionally, it can be hypothesized that via its action
on the tyrosine kinase pathway, insulin can reduce intracellular signals that lead to the
production of inflammatory molecules that possess negative inotropic properties, including
tumor necrosis factor.12
Recognizing that numerous clinical trials of GIK infusion in various critically ill populations
have been conducted over the past 4 decades, we hypothesized that their results could be
aggregated to produce more definitive conclusions about the treatment effect of GIK
infusion in the critically ill. Therefore, we conducted a systematic review and meta-analysis
to examine the available evidence investigating GIK treatment of critically ill patients; our
goal was to determine the treatment effect of such a strategy on mortality and to determine
whether certain predefined subpopulations (patients with septic shock or other forms of
circulatory shock) are afforded survival benefit with GIK treatment.
METHODS
Search Strategy for Identification of Studies
We followed a written protocol that was designed in accordance with recommended
guidelines and finalized prior to beginning the study.13 We searched MEDLINE (1965 to
April 2008), EMBASE (1974 to April 2008), and CINHAL (1982 to April 2008) using the
following search terms: (critical care or intensive care unit or CABG or coronary artery
bypass or cardiac surgery or heart surgery or myocardial infarction or stroke or sepsis or
shock) and (GIK or glucose–insulin–potassium or glucose-insulin or glucose or insulin or
hyperinsulinemia-euglycemia) and clinical trial. The search was updated in October 2008.
To identify potential unpublished data, we contacted 2 experts in the field of critical care,
searched abstracts from the Society of Critical Care Medicine and American College of
Chest Physicians annual meetings from 1997 to 2007, reviewed published practice
guidelines for critical care from 2000 to 2007, and searched Web sites containing details for
clinical trial registration. Additionally, reference lists of the articles chosen for inclusion and
the reference lists of previous reviews3,4,14,15 were screened to identify further studies for
inclusion.
Inclusion Criteria
We considered studies eligible for review, regardless of language or publication type, if they
were randomized controlled trials of human adults (age >17 years) with critical illness
(defined as either patients enrolled in an intensive care unit [ICU] or operating room or a
control group with a mortality rate of greater than or equal to 15%) that had (1) a clearly
defined control group in which patients received standard of care therapy or placebo and (2)
an intervention group in which patients received a continuous infusion of insulin, glucose,
and potassium. Reviews, correspondence, editorials, and nonhuman studies were excluded;
however, their reference lists were screened, if relevant, to identify further studies for
inclusion. We attempted to contact corresponding authors for clarification of missing or
incomplete data.
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Study Selection and Data Abstraction
Two reviewers (MAP and AEJ) independently screened the titles and abstracts of identified
studies for potential eligibility. After the relevance search, the 2 reviewers compared their
exclusion logs, and the κ statistic was calculated to assess interobserver agreement. Cases of
disagreement were resolved by conference between the reviewers. If agreement could not be
reached, the full manuscript was obtained for review.
The full manuscript of each study that passed the relevance screen was reviewed by 2 of the
investigators (MAP and MSR). Study data were abstracted independently by each reviewer
using a standardized data collection form. In cases of disagreement in abstracted data, a third
reviewer abstracted the data and consensus was reached by conference between the 3
reviewers.
Assessment of Quality
Quality was assessed using the Cochrane Collaboration’s tool for assessing the risk of bias
evaluating 4 domains13:
A. Sequence generation: grade A = sequence was adequately generated, grade B =
sequence was inadequately generated, grade C = unknown.
B. Concealment allocation: grade A = performed concealment allocation, grade B =
did not use concealment allocation, grade C = unknown.
C. Blinding: grade A = investigators blinded to allocation, grade B = investigators not
blinded to allocation, grade C = unknown.
D. Selective outcome reporting: grade A = free of suggestion of selective outcome
reporting, grade B = suggestion of selective outcome reporting, grade C =
unknown.
Main Outcome Measure
We defined mortality at the end of the time frame reported by the authors to be the primary
dependent variable for analysis. In the event authors reported mortality at more than one
time point, we used inhospital mortality preferentially.
Statistical Analysis
All data were entered into StatsDirect version 2.7.2 (StatsDirect, Cheshire, UK).
Heterogeneity was tested using a chi-square test with a P value <.10 to indicate significant
heterogeneity between the trials. In addition, I2 was calculated to provide an estimate of the
variability across studies beyond that attributable to chance.16 The results of studies were
pooled using a random effects model.17 The individual and pooled statistics were calculated
as odds ratios (ORs) with 95% confidence intervals (CIs). The validity of using funnel plots
and formal statistical methods to detect the presence of publication bias has recently been
called into question; therefore, a funnel plot was constructed for visual inspection but we do
not attempt to explain any asymmetry.18,19 Additionally, we collected data on the adverse
events of hypoglycemia and hyperkalemia, as defined by the authors of the respective
publications, in the control and GIK arms. We report them as a proportion of the total
enrolled populations among the publications that reported adverse events and according to
the respective study group.
Subgroup and Sensitivity Analysis
Given the large amount of clinical heterogeneity attributable to our definition of critically ill
patients and the wide range of year of publication and practice style, we conducted the
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following a priori defined subgroup analyses: (1) high-quality studies (studies rated grade A
for at least 3 of 4 quality domains previously discussed; (2) studies of patients with septic
shock (using standard criteria); and (3) studies of patients with other forms of circulatory
shock (as defined by each study). Finally, a sensitivity analysis was performed to examine
the use of a fixed effect versus random effects model.
We performed a post hoc (not described in our original protocol) analysis of patients with
acute myocardial infarction (AMI) only and those undergoing cardiovascular surgery (CVS)
only. We chose to perform these subgroup analyses after data collection given that these
were the only 2 patient populations represented in the included studies.
RESULTS
Search and Selection
The comprehensive search yielded a total of 1720 relevant publications; details of the search
and study selection are provided in Figure 1 and Table I.
Inclusion
After the relevance search (blinded interobserver agreement of 98% with 30 disagreements
among 1720 articles, κ = 0.79), a complete manuscript review was performed on 71 articles;
1 article was unobtainable for review despite multiple requests to the National Libraries of
Medicine, Online Computer Library Center, Pramukh Swami Medical College Library
(India), PSG Institute of Medical Sciences and Research (India), Regional Medical Research
Centre for Tribals Central Library (India), KG Medical University (India), and e-mail
requests to the editor of the journal and all of the primary and secondary authors.
A total of 23 studies met our predefined criteria and were included in the final analysis,
providing a total sample of 22 525 patients.2,20–41 Three full-length articles were translated
to English from French,23 Turkish,31 and Chinese.40 All 3 met our criteria and were
included in the final analysis.
Study Descriptions
The incidence of mortality in the studies ranged from 0 to 36% in the control group and 0 to
16% in the study group. Nine studies took place in an ICU, 13 studies took place in an
operating room, and in 1 study the location was unclear but the predefined control group
mortality rate allowed inclusion of the study. Pertinent details of the included studies are
provided in Table II.
Quality Assessment
Two authors (MAP, MSR) independently graded the publications on the measures of
sequence generation, concealment of allocation, blinding, and selective outcome reporting.
Four studies were graded A in 3 of 4 criteria,2,35,38,39 meeting our definition of high quality.
Analyses
When all 23 studies were considered, there was no evidence of statistical heterogeneity (P
= .57; I2 = 0%); however, there was clinical heterogeneity among the studies. The summary
OR demonstrates no significant reduction in mortality (OR = 1.02; 95% CI, 0.93–1.11)
among subjects receiving GIK (Figure 2). To assess for potential publication bias, a funnel
plot of all included studies is provided in Figure 3.
Subgroup analysis of high-quality studies (defined above and shown in Table 2), studies
with only AMI patients (10 studies, Table 2), and studies with only CVS patients (13
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studies, Table 2) similarly showed no mortality reduction among subjects who received GIK
(OR = 1.04; 95% CI, 0.95–1.14 for high-quality studies; OR = 0.98; 95% CI, 0.81–1.19 for
AMI studies; and OR = 0.70; 95% CI, 0.29–1.72 for CVS studies). None of the above point
estimates were significantly different when using a fixed effect model.
Of the 22 525 patients included in the final analysis, 20 195 (89.7%) were enrolled in a
single, multi-center study of GIK in AMI patients.2 We performed a post hoc analysis to
determine whether this study was dominating the model because of its size. When this study
was excluded and the analysis repeated, there was no significant difference in the treatment
effect (OR = 0.78; 95% CI, 0.54–1.11).
Table III provides a summary of all of the studies involving GIK administration to patients
with septic shock.42–47 None of the studies with septic shock populations were randomized
trials; thus, none were appropriate for inclusion in our meta-analysis. Additionally, our
comprehensive literature search did not identify any randomized trials of GIK treatment in
other circulatory shock populations, and no subpopulations of circulatory shock patients
were reported in any of the studies meeting our inclusion criteria.
Six studies2,29,36,37,39,40 explicitly reported the number of occurrences of hypoglycemia,
and among these studies the incidence of hypoglycemia in GIK patients was 0.5% (54/10
324) and in controls was 0.1% (11/10 309). Four studies2,31,36,40 explicitly reported the
number of occurrences of hyperkalemia, and among these studies the incidence of
hyperkalemia was 4.3% (434/10 166) in GIK patients and 1.6% (161/10 147) in controls.
DISCUSSION
This meta-analysis evaluates the treatment effect of GIK therapy in critically ill patients.
Using pooled data from 23 studies that randomized a total of 22 525 subjects, we found no
significant effect on mortality (OR = 1.02; 95% CI = 0.93–1.11). We identified no studies
that included septic shock or other forms of circulatory shock patients in an experimental
design. Of the studies reporting adverse events, hyperkalemia occurred more commonly than
hypoglycemia; however, both had low cumulative incidence.
This systematic review used both a comprehensive search and standard methods for
summarizing the treatment effect of GIK therapy in critically ill patients. The subgroup
analyses we present included the high-quality studies, studies with AMI populations only,
and studies with CVS populations only. None of these analyses demonstrated significant
mortality benefits associated with administration of GIK. Our other subgroup analyses were
to examine only populations of septic shock and other forms of circulatory shock; however,
we were unable to identify any experimental studies examining these groups of patients.
This was surprising to us given the amount of basic science research that supports the
potential physiological benefits of GIK therapy for septic shock.48–52 Because we
specifically sought out studies of septic shock and were unable to include any in the
analysis, this study adds to previously published meta-analyses of GIK by allowing a
conclusion that the current literature provides an absence of evidence regarding the effect of
GIK as a therapy for septic shock.
It is important to note the clinical heterogeneity among the studies included in this analysis.
All of the included studies were either in patients with the diagnosis of AMI (10 studies) or
in CVS patients (13 studies). Thus, our results are limited to those populations and should
not be extrapolated to heterogeneous groups of critically ill patients or those with other
diagnoses such as acute respiratory distress syndrome or sepsis. Furthermore, the studies in
this analysis span a time frame of 40 years. Many new therapeutic options, particularly for
myocardial infraction and cardiothoracic surgery, have changed during this time. A
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limitation of this meta-analysis is the possibility that co-interventions (eg, thrombolytic or
percutaneous coronary angioplasty) may have influenced the results of included studies;
there was no practical way to capture or control for such interventions in this meta-analysis.
One previous meta-analysis, by Pittas et al, examined the effect of insulin therapy for
critically ill hospitalized patients.15 Pittas et al found that insulin therapy initiated in the
hospital has beneficial effects on short-term mortality in critically ill patients. There are
several plausible explanations for the different findings between the Pittas study and the
present analysis. First, the Pittas analysis included studies in which patients were treated
with any type or form of insulin therapy, whereas we limited our inclusion to only studies
that administered a GIK solution. Second, the Pittas study used a broad definition of critical
illness by including all patients with AMI and stroke and those in the ICU or operating
room. This broad inclusion may have resulted in misclassification of critical illness and
affected the results. The definition of critical illness used in the present analysis was more
conservative, most likely resulting in a more homogenous sample. Finally, the sample of
patients in this meta-analysis is 5 times larger (22 525 vs 4733) than the sample of subjects
that received GIK in the Pittas study, resulting in a much higher power to detect the true
treatment effect.
As previously mentioned, 20 195 of the 22 525 (89.7%) subjects included in this meta-
analysis were from a single publication (Mehta et al2). In an attempt to control for the
potential for this study to dominate the analysis, we performed a subgroup analysis where
we excluded this report from the analysis and re-performed the statistical model. The
resulting odds ratio was 0.78 (95% CI, 0.54–1.11), and although this was not statistically
significant, there is clearly a trend toward improvement in mortality with the odds ratio well
below 1 and the upper bounds of the confidence interval just above 1. This suggests that this
large study had an important influence on our overall results; however, we are reassured by
the finding that the statistical significance of the subgroup analysis (nonsignificant mortality
reduction) was the same as our overall findings.
Any meta-analysis is prone to bias given its retrospective approach; however, we used a
number of important steps in an attempt to minimize the impact of bias. First, we followed a
protocol that was written prior to starting the search and analysis. Second, we used
independent observers to both abstract data and grade study quality. Third, our meta-
analysis addressed all of the suggested necessary components of the AMSTAR
methodological quality measurement tool for systematic reviews.53
CONCLUSION
Data synthesized from 23 randomized controlled trials demonstrated no treatment effect of
GIK therapy in critically ill patients; however, study populations included were limited to
acute myocardial infarction and cardiovascular surgery patients. No studies were identified
that used GIK in patients with septic shock or other forms of circulatory shock, providing an
absence of evidence regarding GIK as a treatment for shock. Adverse events related to GIK
infusion were uncommon. Future studies should explore the potential benefits of GIK in
sepsis, shock, or other heterogeneous critically ill populations in experimental research
designs.
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Figure 1.
Search, inclusion, and exclusion flow diagram.
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Figure 2.
Forest plot of all included studies. Odds ratios with 95% confidence intervals are shown on
the right and the corresponding study is shown on the left. *Studies that were excluded from
the summary odds ratio calculation because there were no occurrences of the primary
outcome in the study.
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Figure 3.
Funnel plot of included studies. Individual included studies are represented by dots and are
plotted by the standard error (SE) on the y-axis and the log odds ratio on the x-axis. This
plot is provided for visual inspection for detection of publication bias.
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Table I
Primary Reason for Study Exclusion
After relevance screen
 Review/letter/editorial 384
 Nonrandomized/nontreatment study 20
 Wrong focus or population 1244
After full manuscript review
 Review article 1
 Duplicate publication 4
 Not critically ill 16
 Wrong outcome 18
 Wrong treatment 5
 Wrong focus or population 3
 Manuscript unobtainable for review 1
After attempted author contact
 Failed author contact 1
 Total 1697
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